Additional Indications Approved

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

 

Approved Additional Indication DCA 336

Approved Additional Indication DCA 335

Approved Additional Indication DCA 334

Approved Additional Indication DCA 333

Approved Additional Indication DCA 332

Approved Additional Indication DCA 331

Approved Additional Indication DCA 330

Approved Additional Indication DCA 329

Approved Additional Indication DCA 328

Approved Additional Indication DCA 327

Approved Additional Indication DCA 326

Approved Additional Indication DCA 324

Approved Additional Indication DCA 323

Approved Additional Indication DCA 322

Approved Additional Indication DCA 321

Approved Additional Indication DCA 320

Approved Additional Indication DCA 319

Approved Additional Indication DCA 318

Approved Additional Indication DCA 317

Approved Additional Indication DCA 316

Approved Additional Indication DCA 315

Approved Additional Indication DCA 314

Approved Additional Indication DCA 313

Approved Additional Indication DCA 312

Approved Additional Indication DCA 310

Approved Additional Indication DCA 308

Approved Additional Indication DCA 307

Approved Additional Indication DCA 306

Approved Additional Indication DCA 305

Approved Additional Indication DCA 304

Approved Additional Indication DCA 303

Approved Additional Indication DCA 301

Approved Additional Indication DCA 300

Approved Additional Indication DCA 299

Approved Additional Indication DCA 295

Approved Additional Indication DCA 294

Approved Additional Indication DCA 293

Approved Additional Indication DCA 292

Approved Additional Indication DCA 291

Approved Additional Indication DCA 290

Approved Additional Indication DCA 289

Approved Additional Indication DCA 288

Approved Additional Indication DCA 287

Approved Additional Indication DCA 286

Approved Additional Indication DCA 284

Approved Additional Indication DCA 283

Approved Additional Indication DCA 282

Approved Additional Indication DCA 281

Approved Additional Indication DCA 280

Approved Additional Indication DCA 279

Approved Additional Indication DCA 277

Approved Additional Indication DCA 275

Approved Additional Indication DCA 274

Approved Additional Indication DCA 273

Approved Additional Indication DCA 272

Approved Additional Indication DCA 271

Approved Additional Indication DCA 269

Approved Additional Indication DCA 268

Approved Additional Indication DCA 267

Approved Additional Indication DCA 266

Approved Additional Indication DCA 265

Approved Additional Indication DCA 264

Approved Additional Indication DCA 263

Approved Additional Indication DCA 262

Approved Additional Indication DCA 261

Approved Additional Indication DCA 260

Approved Additional Indication DCA 259

Approved Additional Indication DCA 258

Approved Additional Indication DCA 257

Approved Additional Indication DCA 256

Approved Additional Indication DCA 253

Approved Additional Indication DCA 252

Approved Additional Indication DCA 250

Approved Additional Indication DCA 248

Additional Indications Approved / Archives

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Newsletter Subsription

Site Last Modified

  • Last Modified: Thursday 15 August 2019, 09:10:04.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language